Stevanato Group S.p.A.
Stevanato Group (STVN) reported Q2 revenue of €302.0M, up 8% YoY, and sold subsidiary Balda C. Brewer. High-value solutions grew 16% to €135.9M, driving margin improvements. Adjusted net profit rose 20% to €37.6M. Full-year revenue guidance narrowed to €1.28B. Hedge fund ownership fell to 18 from 21.
Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.
Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.
Over the past 7 days, alphai's AI scored 1 news story mentioning STVN (Stevanato Group S.p.A.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent STVN coverage spans earnings, financial news and regulation.
In the last 30 days, STVN insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($166K). The most active reporter was Santel Luciano with 1 filing.
Positive earnings beat and higher margins may support short‑term price upside; however, negative free cash flow and debt level add downside risk.
Guidance adjustment plus Alina variable dose pen regulatory approvals and GLP-1/biologics momentum are likely to support higher expectations for 2026-2027 revenue mix.
Q2 results and operational updates (divestiture, margin drivers, order wins, and capacity milestones) provide near-term read-through on execution and demand for differentiated drug delivery.
Earnings beat on revenue and margin, guidance raised; likely supportive for stock.
Guidance update and segment performance (BDS growth, Engineering decline) plus one-time divestiture costs change the earnings outlook and margin trajectory.
alphai scores every news story that mentions STVN with an AI model for sentiment and relevance, and aggregates insider trades from Stevanato Group S.p.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stevanato Group (STVN) reported Q2 revenue of €302.0M, up 8% YoY, and sold subsidiary Balda C. Brewer. High-value solutions grew 16% to €135.9M, driving margin improvements. Adjusted net profit rose 20% to €37.6M. Full-year revenue guidance narrowed to €1.28B. Hedge fund ownership fell to 18 from 21.
2 min readStevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.
6 min readStevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.
7 min readStevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of
2 min readStevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.
6 min readStevanato Group S.p.A. (NYSE: STVN) said liraglutide-based combination products using its Alina variable-dose pen injector received marketing authorizations in multiple European countries. The approvals cover Alina 30 for diabetes and Alina 50 for weight management. Stevanato said the device platform supports scalable manufacturing and integration into existing fill-finish supply chains.
4 min readStevanato Group S.p.A. (NYSE:STVN) experienced a decline in Q1 2026, as noted by Conestoga Capital Advisors in their investor letter. The company's stock struggled due to investors weighing solid results against a mixed underlying business mix and moderating growth profile, with overall revenue growth remaining relatively modest at 5%. Despite improved margins and scaling high-value solutions, the stock was pressured by weakness in the Engineering segment, a transition towards higher-value products, and the decline of oral vs. GLP-1s.
4 min readImage source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readInvestors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR ( SDZNY Quick QuoteSDZNY - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer ...
4 min readInvestors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences ( USNA Quick QuoteUSNA - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
4 min read
